CHEST 2023 On Demand Pass-How to Handle the Com-PLEX-ity of Antibodies in Lung Transplantation

How to Handle the Com-PLEX-ity of Antibodies in Lung Transplantation

Video Transcription

Video Summary

In this video, the speaker discusses the importance of antibodies in the context of transplantation, specifically lung transplantation. They explain that antibodies can be a barrier to successful transplantation and can lead to poor outcomes, such as graft rejection and decreased survival. The speaker outlines different treatment options for antibody-mediated rejection (AMR). These options include plasmapheresis and IVIG, rituximab, Bortezomib, Carfilzomib, Daratumumab, tocilizumab, clazokizumab, eculizumab, and other investigational agents. The speaker discusses the limited evidence for the effectiveness of these treatments and emphasizes the need for further research in this area. They also highlight the importance of risk stratifying pre-transplant recipients based on their level of sensitization and antibody titers, and they discuss the potential options for transplanting highly sensitized individuals. Overall, the video provides an overview of the role of antibodies in transplantation and the current treatment options available.

Meta Tag

Category Transplantation

Session ID 1107

Speaker Adam Cochrane

Speaker Michelle Hickey

Speaker Deborah Levine

Speaker Naureen Narula

Track Transplantation

Keywords

antibodies

transplantation

graft rejection

antibody-mediated rejection

treatment options

sensitization

antibody titers

research

highly sensitized individuals